Merck’s WELIREG meets primary endpoint of PFS in Phase 3 RCC trial

Global pharmaceutical leader Merck has announced that WELIREG (belzutifan), its pioneering oral HIF-2α inhibitor, has achieved a critical milestone in its Phase 3 trial LITESPARK-005. ... Read More